Literature DB >> 9314351

Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma.

M Majori1, M L Piccoli, S Bertacco, A Cuomo, L Cantini, A Pesci.   

Abstract

BACKGROUND: Previous studies demonstrated a downregulation of T-lymphocyte (CD3+ cells) activation in peripheral blood after treatment with inhaled corticosteroids in patients with asthma.
OBJECTIVE: This study was carried out to evaluate the effect of inhaled corticosteroids on CD4 and CD8 T-lymphocyte activation, respectively.
METHODS: We examined the expression of three surface activation markers (CD25, HLA-DR, and very late activation antigen 1) on circulating CD4+ and CD8+ T-cell subsets in subjects with asthma (n = 23) before and 8 weeks after treatment with inhaled beclomethasone dipropionate dry powder (daily dose, 800 microg).
RESULTS: Beclomethasone dipropionate treatment had a marked effect in reducing the expression of the activation marker CD25 (p < 0.01) in both CD4+ and CD8+ T-cell subsets in peripheral blood of patients with asthma. However, no correlation was found between the downregulation of CD4 and CD8 T-lymphocyte activation and the improvement in physiologic indices of disease activity.
CONCLUSIONS: These data add to the view that CD4+ and CD8+ T lymphocytes in peripheral blood of patients with asthma are in an activated state that is downregulated by inhaled corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314351     DOI: 10.1016/s0091-6749(97)70252-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

2.  AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity.

Authors:  Nicholas W Lukacs; Aaron Berlin; Dominique Schols; Renato T Skerlj; Gary J Bridger
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

3.  Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats.

Authors:  Zhenling Yao; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 4.  Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.

Authors:  Kian Fan Chung; Gaetano Caramori; Ian M Adcock
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

5.  Expression of naive/memory (CD45RA/CD45RO) markers by peripheral blood CD4+ and CD8 + T cells in children with asthma.

Authors:  Edyta Machura; Bogdan Mazur; Wojciech Pieniazek; Krystyna Karczewska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-02-05       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.